BIOMARK’S LIQUID BIOPSY ASSAY LEVERING METABOLOMICS DEMONSTRATES STRONG PERFORMANCE FOR EARLY LUNG CANCER DETECTION

Vancouver, British Columbia – ( March 24th, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the article “A High-Performing Plasma Metabolite Panel for Early-Stage Lung Cancer Detection” has been published in the peer-reviewed journal Cancers, validating BioMark’s technology to detect early-stage (I/II) non-small cell lung cancer (NSCLC) using a simple blood plasma test.

Rashid Bux, President and CEO, says, “This latest publication demonstrates our ability to further leverage our international team of leading clinicians, scientists, researchers and data scientists in discovery and validation studies for the development of early detection lung cancer diagnostic assay. The objective of the research was to use metabolomic techniques to discover and validate plasma metabolite biomarkers for the diagnosis of early-stage non-small cell lung cancer. The study included plasma samples from patients with biopsy-confirmed NSCLC along with age and gender-matched plasma samples from healthy controls. Robust predictive models were developed and validated using these metabolites and other, easily measured clinical data for detecting different stages of NSCLC. This study successfully identified and validated a simple, high-performing, metabolite-based test for detecting early stage (I/II) NSCLC patients in plasma.”

The team consisted of Dr. David Wishart (Department of Biological Sciences, University of Alberta, Edmonton, AB), Lun Zhang (Department of Biological Sciences, University of Alberta, Edmonton, AB) Dr. Rupasri Mandal (Department of Biological Sciences, University of Alberta, Edmonton, AB) , Jiamin Zheng (Department of Biological Sciences, University of Alberta, Edmonton, AB) Jennifer Reid Department of Biological Sciences, University of Alberta, Edmonton, AB) Dr. Andrew Maksymiuk (CancerCare Manitoba),  Daniel Sitar (Department of Internal Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba), Bram Ramjiawan (Asper Clinical Research Institute & Office of Clinical Research, St. Boniface Hospital, Winnipeg, Manitoba), Paramjit Tappia (Asper Clinical Research Institute & Office of Clinical Research, St. Boniface Hospital, Winnipeg, Manitoba), Dr. Christian Rolfo (Marlene and Stewart Greenebaum Comprehensive Cancer Centre, University of Maryland, School of Medicine Baltimore), and Alessandro Russo (Medical Oncology Unit A.O. Papardo & Department of Human Pathology, University of Messina).

The recently published paper is available through:

https://www.ncbi.nlm.nih.gov/pubmed/32156060 and Cancers 2020, 12(3), 622; https://doi.org/10.3390/cancers12030622

“While very promising, further validation on larger and more diverse cohorts is still required. BioMark has commenced a Pan-Canadian collaboration with leading clinicians, scientists, biobank, leading research institutions, machine learning analysts, accredited lab, regulatory advisors and health technology assessment specialists to prime and develop the assay for early lung cancer detection and screening application which has significant global demand given the limitation of existing tests. The technology works, and we’ve been able to show that this is a superb experimental platform with major clinical potential,” says Rashid Bux. A key advantage of developing a blood based metabolomic test is that it can be easily converted into a low-cost, high-throughput assay that can be run at almost any clinical laboratory equipped with a standard triple-quadrupole mass spectrometer very efficiently. We estimate that a modified assay that is specific to the metabolites identified here require as little as 10 μL of plasma. These promising results suggest that a minimally invasive, high performance, high-throughput, low cost lung cancer screening assay might be developed that could be used to select patients for further follow-up and confirmation using LDCT or other lung imaging modalities.

About Cancers

Cancers (ISSN 2072-6694) is an international, peer-reviewed open access journal on oncology. It publishes article types including Research Papers, Reviews, Editorials, Communications, etc. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. The full experimental details must be provided so that the results can be reproduced.

Scope of Journal

We publish high-quality articles including basic, translational, and clinical studies on all tumor types (https://medlineplus.gov/cancers.html).

Press Release – BIOMARK’S LIQUID BIOPSY ASSAY LEVEARING METABOLOMICS DEMONSTRATES UTILITY IN EARLY LUNG CANCER DETECTION

 

 

BioMark Diagnostics Advanced Raman Spectrometer Could Potentially Serve as Complementary Detection Tool for COVID -19 / Coronavirus

 

  • Originally created as part of the company’s cancer ultra sensitive and small molecule specific detection system, the device has potential to identity many infectious diseases

Vancouver, British Columbia – (March 16, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) a developer of proprietary, non-invasive, and accurate diagnostic solutions which can help detect, monitor and assess cancer early and cost effectively, announced today following their annual technology meeting  that their Advanced Raman Spectrometer might have potential to be modified and reconfigured for use in the detection of  certain pathogens and mutations within the COVID-19, Coronavirus.

BioMark’s Raman Spectrometer was originally developed for work in early cancer diagnostics. It was created to assist in ultra-low detection of a very small exogenous molecule in urine samples. The size of the molecule is much smaller than that of a typical virus. Additionally, at the time BioMark believed there was realistic potential for its use in identifying infectious diseases. In 2014 Ebola was a serious concern in West Africa and BioMark felt it may be an ideal candidate for field testing.

An effective pathogen testing solution requires a device that is affordable and rapidly deployable. It should also utilize wireless or satellite technology to communicate with the World Health Organization (WHO) or Center for Disease Control (CDC).  BioMark’s Raman Spectrometer could not only share information amongst test sites, but in theory, could potentially be re-configured if a pathogen mutates and the RNA or DNA.

“Testing is critical to understand the both the scope of the disease and to provide effective treatment to those afflicted.  More efficient testing provides physicians with greater knowledge as to how the disease evolves, lends insight as to the precautions we can take stop it from spreading,” stated Mr. Rashid A. Bux, President & CEO of BioMark Diagnostics, Inc. “BioMark could leverage its years of scientific research and development to prepare for rapid and sensitive means of detecting viruses and the emergence of new pathogens. A modified Raman Spectrometer in combination with advanced statistical methods coupled with other technology and strategic relationships will allow us to continue to develop and enhance new solutions that provide early detection to many of the world’s most dangerous diseases.”  In addition, Raman can be performed effectively on “bulk” vs single sample analysis.

“The BRS785 is a modular spectrometer. The key feature of the BRS785 is a novel integrated Raman probe that features high output power with ultra-narrow spectral bandwidth and a circularized and collimated output beam with optics and interference filters to provide remarkable performance for a spectrometer of its size.”


BioMark Press Release – Raman System Potential For Viral Detection

BioMark’s Market Update Report

Vancouver, British Columbia – (February 4th, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to provide a market update report with key activities undertaken by BioMark’s team during January 2020.

 

“BioMark is not aware of any negative news that has impacted its share price recently. We continue to execute well as discussed in our 2019 Round Up and Outlook for 2020 yearend report. I would like to share with you some key activities undertaken by BioMark’s team during January 2020 that demonstrates our commitment to achieve our goals in 2020 says”, Rashid Ahmed CEO and President of BioMark.

 

  • BioMark team attended MEDTEQ Innovation Summit on January 13 -16, 2020 in Montreal, met with MEDTEQ team and discussed funding application status which is currently being reviewed by the Government of Quebec economic team. The funding is for over $650,000.
  • BioMark team met with Canada Brain Foundation to explore potential grants and funding for brain related projects across Canada. This is timely given our breakthrough research being conducted in Glioblastoma (aggressive brain cancer) and is being led by Dr. Don Miller and his team.
  • BioMark team presented at IUCPQ in Quebec City and managed to review and discussed the large prospective study plan with Dr. Joubert and the IUCPQ biobank team. We anticipate to source samples from the IUCPQ’s well established biobank.
  • BioMark will present a proposal for the board of IUCPQ. The outcome of the board decision will be shared later in February 2020 based on a favourable response.
  • BioMark team met with other potential partners in Quebec that will assess opportunity to collaborate on the Pan Canadian Lung Cancer Screening program.
  • BioMark signed a confidentiality agreement with a leading US based genetic test service provider that offers over 4000 genetic based tests to 40 states across USA. Discussions between our mutual scientific teams were held in during the third week of January.
  • BioMark completed drafts related to clinical trial protocols for the upcoming multi centre Chinese Lung Cancer study that will be using an FDA approved drug (rimantadine) as a probe. Meetings were held with a principal scientist leading the project in China prior to the coronavirus global alert. Appropriate milestone payments were received on time as outlined in the agreement between the two parties.
  • BioMark developed synthesized internal standards needed for analysis of urine samples for rimantadine clinical trials in China. The certificate of analysis has also been produced to demonstrate the quality standards necessary for regulatory rigor.
  • New patents for Canada and US have been reviewed and are being filed to protect our new discoveries.
  • BioMark’s certified and accredited lab BRI has completed the development of 12 internal standards that will be used as an assay to assess response to treatment for lung cancer patients following chemo and radio therapy. The result of this proof of concept studies if successful will be another important clinical success for our amantadine and related metabolite panel. The ability to assess faster response will allow for more expedient treatment options for the patients leading to potentially better outcome.

 

About IUCPQ

The Quebec Heart and Lung Institute Research Centre is the only centre funded by the Fondsde recherche du Québec – Santé (FRQS) that regroups three research components (cardiology, respirology and obesity-metabolism) deemed to be a priority because of the considerable economic and social impact of their related diseases.

 

Research with far-reaching effects

The centre’s research themes are central to global health priorities and a major strategic force for halting the progress of non-communicable chronic diseases and their devastating effects. According to the World Health Organization (WHO), non-communicable chronic diseases (cardiovascular diseases, respiratory diseases, diabetes and cancer) are responsible for 63% of deaths worldwide. Obesity, which has reached global epidemic proportions, is one of the greatest risk factors for these diseases.

 

An integrated research approach

The centre is unique in that our research components perfectly complement the Institute’s clinical missions. This enables health professionals and researchers to work in total synergy to the greatest benefit of patients. This synergy turns research findings into better care in harmony with the vision of the FRQS and of the Canadian Institutes of Health Research (CIHR).Our research teams harness this synergy for the integrated study of the metabolic triggers of cardiovascular and lung diseases, as well as to develop innovative and competitive Quebec research in disease prevention and treatment. In addition, our unique research-care paradigm allows us to identify research priorities according to the clinical issues arising from the Institute’s subspecialties.

 

About MEDTEQ

MEDTEQ’s mission is, through collaborative, industry led projects, to accelerate innovation and position, on a global scale, products and services developed by the Canadian medical technologies industry, thereby generating major economic impacts while improving healthcare systems for the ultimate benefit of patients in Canada and around the world.  Medteq is a voice in setting health technologies standards, best practices and processes, including privileged access to 180+ member companies, health centres, universities and investors.

 

MEDTEQ’S Vision 2025

With a dual provincial and federal mandate, MEDTEQ continues to be a focus point for Canada’s medical technology sector in terms of research, innovation and the integration of leading-edge solutions in the delivery of health care.

Press Release – BioMark’s Market Update .doc

BIOMARK’S SCIENTIFIC ADVISOR NAMED DEAN OF SCHULICH SCHOOL OF MEDICINE AND DENTISTRY

Vancouver, British Columbia – (January 21, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) and its team of scientific advisors would like to congratulate Dr. John Yoo  for being named Dean of the Schulich School of Medicine & Dentistry on January 6th, 2020.

Dr. Yoo has an international reputation as a pioneering surgeon and an exemplary academic and clinical leader. He currently serves Western as Interim Chair/Chief of the Department of Paediatrics, as Fellowship Director for the Department of Otolaryngology – Head & Neck Surgery, and as a Professor of Otolaryngology and Oncology. Prior to these roles, Dr. Yoo served as Chair/Chief of the Department of Otolaryngology – Head & Neck Surgery for 10 years. As a surgeon, Dr. Yoo pioneered and popularized a technique for reconstructive facial surgery that has been adopted around the world. He has served as Co-Chair of the London Health Sciences Centre’s Facial Nerve Clinic since 2007. Today, in addition to his academic, leadership and clinical roles, Dr. Yoo serves as the Co-chair of Cancer Care Ontario Head and Neck Cancer Disease Site, is the President-elect of the Canadian Association of Head and Neck Surgical Oncology and is an executive board member with the Canadian Association of Otolaryngology and the Asia-Pacific Society of Thyroid Surgery, and he was the longest-serving Chair of the Canadian Chairs of Otolaryngology.

Dr. Yoo will step into his new role as Schulich Medicine & Dentistry’s next Dean on May 1, 2020.

“BioMark would like to take this opportunity to wish Dr. Yoo the very best in his new role. His vision, passion to inspire and guide individuals and institutions is exemplary. BioMark is fortunate to have been supported with his counsel in establishing a rigorous emphasis to focus on end point driven clinical research” says BioMark ‘s CEO and President Rashid Ahmed.

ABOUT WESTERN

Western University delivers an academic experience second to none. Since 1878, The Western Experience has combined academic excellence with life-long opportunities for intellectual, social and cultural growth in order to better serve our communities. Our research excellence expands knowledge and drives discovery with real-world application. Western attracts individuals with a broad worldview, seeking to study, influence and lead in the international community.

ABOUT THE SCHULICH SCHOOL OF MEDICINE & DENTISTRY


The Schulich School of Medicine & Dentistry at Western University is one of Canada’s preeminent medical and dental schools. Established in 1881, it was one of the founding schools of Western University and is known for being the birthplace of family medicine in Canada. For more than 130 years, the School has demonstrated a commitment to academic excellence and a passion for scientific discovery.

ABOUT LONDON HEALTH SCIENCES CENTRE

London Health Sciences Centre has been at the forefront of medicine in Canada for 145 years and offers the broadest range of specialized clinical services in Ontario. Building on the traditions of its founding hospitals to provide compassionate care in an academic teaching setting, London Health Sciences Centre is home to Children’s Hospital, University Hospital, Victoria Hospital, the Kidney Care Centre, two family medical centres, and two research institutes – Children’s Health Research Institute and Lawson Health Research Institute. As a leader in medical discovery and health research, London Health Sciences Centre has a history of over 70 international and national firsts and attracts top clinicians and researchers from around the world. As a regional referral centre, London Health Sciences Centre cares for the most medically complex patients including critically injured adults and children in southwestern Ontario and beyond. The hospital’s nearly 15,000 staff, physicians, students and volunteers provide care for more than one million patient visits a year.

Press Release Dr. John Yoo Appointed Dean of Schulich School of Medicine and Dentistry.doc